局部晚期头颈部癌症患者接受 TPF 诱导化疗完成的预测因素。
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
机构信息
Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
Department of Head and Neck Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
出版信息
Anticancer Res. 2019 Aug;39(8):4337-4342. doi: 10.21873/anticanres.13601.
BACKGROUND
Induction therapy with docetaxel, cisplatin and fluorouracil (TPF) is a treatment option for locally advanced head and neck cancer (LAHNC), but it is not known which patients are appropriate for TPF.
PATIENTS AND METHODS
We retrospectively reviewed the records of patients with LAHNC who underwent induction TPF, and evaluated factors predictive of the completion of TPF treatment (defined as ≥3 cycles administered).
RESULTS
Of the total 93 enrolled patients, 73 (78.5%) achieved therapy completion. In a multivariate analysis, hypolaryngeal/ laryngeal primary tumor site was a negative predictive factor (hazard ratio(HR)=0.32, 95% confidence interval(CI)=0.11-0.96, p=0.041) and body mass index ≥22 kg/m was a positive predictive factor (hazard ratio=3.51, 95% confidence intervaI=1.04-11.83, p=0.043) of TPF completion.
CONCLUSION
For patients with LAHNC, oropharyngeal primary tumor site and high body mass index can be used to predict TPF completion and may contribute to decisions on the indications for TPF in terms of safety and tolerability.
背景
多西他赛、顺铂和氟尿嘧啶（TPF）诱导疗法是局部晚期头颈部癌症（LAHNC）的一种治疗选择，但尚不清楚哪些患者适合 TPF。
患者和方法
我们回顾性分析了接受诱导 TPF 治疗的 LAHNC 患者的病历，并评估了预测 TPF 治疗完成（定义为至少接受 3 个周期治疗）的因素。
结果
在总共 93 名入组患者中，有 73 名（78.5%）完成了治疗。多变量分析显示，下咽/喉原发肿瘤部位是一个负预测因素（风险比（HR）=0.32，95%置信区间（CI）=0.11-0.96，p=0.041），而体重指数≥22 kg/m 是 TPF 完成的一个正预测因素（HR=3.51，95%置信区间（CI）=1.04-11.83，p=0.043）。
结论
对于 LAHNC 患者，口咽原发肿瘤部位和高体重指数可用于预测 TPF 完成情况，这可能有助于根据安全性和耐受性来决定 TPF 的适应证。
Zotero 插件